Kura Oncology Inc. (KURA)
Kura Oncology Inc. (KURA) Stock Price, Analysis & Data
| Bid | 7.78 |
| Market Cap | 966.11M |
| Revenue (ttm) | 77.22M |
| Net Income (ttm) | -296.78M |
| Beta | 0.38 |
| EPS (ttm) | -3.37 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.72 |
| P/B (ttm) | 8.94 |
| P/S (ttm) | 12.51 |
| Earnings Date | Nov 3, 2026 |
| Ask | 12.74 |
| Volume | 1,854,947 |
| Avg. Volume (20D) | 1,774,650 |
| Open | 9.98 |
| Previous Close | 10.09 |
| Day's Range | 9.94 - 11.01 |
| 52-Week Range | 6.95 - 12.49 |
| Analyst | Strong Buy |
| Price Target | 28 (157.83%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a...
Financial Performance
In 2025, Kura Oncology's revenue was 67.48M, an increase of 25.24% compared to the previous year's 53.88M. Earnings were -278.67M, an increase of 60.17%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for KURA stock is "Strong Buy". The 12-month stock price forecast is 28, which is upside of 157.83% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
